These innovative agents represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose levels. https://cecilyidtd348655.csublogs.com/46685775/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide